Nasdaq GlobeNewswire

VistaJet Leads the Future of Business Travel With VistaJet Direct, Its New Digital Membership

Del

New app is part of the company's vision to continue offering its unparalleled service with a global reach through the exponential power of technology

  • Real-time access to the VistaJet fleet of over 70 silver and red aircraft
  • Priority booking on VistaJet's one-way and empty leg flights
  • Members can plan and request flights with digital visualisation
  • The fastest possible bookings
  • The only end-to-end booking app in business aviation

LONDON, Aug. 30, 2017 (GLOBE NEWSWIRE) -- VistaJet, the first and only global aviation company, has today officially launched VistaJet Direct, the new digital membership offering priority access to VistaJet's one-way and empty leg flights at preferential rates.

Photos accompanying this announcement are available at

http://www.globenewswire.com/NewsRoom/AttachmentNg/3406fd94-1d40-4772-918f-c39f25c50f69

http://www.globenewswire.com/NewsRoom/AttachmentNg/3116b9b8-6762-4f8a-a3a1-684f922dcfac

http://www.globenewswire.com/NewsRoom/AttachmentNg/3ae29f2a-29bf-492e-a5a9-89b87dc2894c

VistaJet sets another milestone of what the future of private travel will look like, becoming the only company in its sector to offer a complete portfolio of flight solutions, with Program, On Demand and the new VistaJet Direct. Busy schedules and last-minute decisions are part of the everyday for most business travelers. The new digital membership is ideal for anyone looking for the unparalleled service and global reach only VistaJet can offer, without any upfront flying commitment.

VistaJet has made headlines through a series of revolutionary initiatives aimed at making flying private simpler than ever. Now the same ease of mind is offered with minimum commitment. A yearly membership of only $10,000 will allow customers to request bookings on all available VistaJet aircraft prior to the charter market.

Unlike some of its competitors that offer seat-only booking and no guarantees, VistaJet Direct gives customers the opportunity to have the full VistaJet experience, including sole use of a jet, a cabin hostess trained by the British Butler Institute, catering from the world's most renowned restaurants, and a comprehensive in-flight service. Once a booking is confirmed, VistaJet guarantees aircraft availability on one of its wholly-owned fleet of over 70 identically designed aircraft, providing peace of mind to its customers.

Through the app's in-built geo-location services, Members will receive a push notification to their smartphone when a flight near them or from their favorite cities is available. All they have to do is tap the notification and book. What's more, the app offers real-time fixed pricing, and the entire booking process can be completed in minutes. To make the booking process even more convenient, customers and their teams can request flights through smartphone app or desktop, being always up to date and controlling everything on their flight from catering to additional ground services.

Thanks to its strategic investment into innovative technology, VistaJet leads the business aviation sector with a pioneering end-to-end technology platform that makes the company the most technologically integrated company in business aviation.

Thomas Flohr, Chairman and Founder said:

"Today's launch is all about giving our customers, and all business travelers, as much flexibility and choice as possible. With the addition of VistaJet Direct, flying with us is easier than ever.
We're always looking for new opportunities to make travel as memorable as possible, and make our customers' flight an experience they will never forget. VistaJet Direct is the fastest and most convenient way to fly VistaJet. Customers can now book a flight and access the full array of our services no matter where in the world they are, at a time that suits them."

Become a VistaJet Direct Member at:
www.vistajet.com/direct                     AppStore                      Google Play

About VistaJet 
VistaJet is the first and only global aviation company. On its fleet of silver and red business jets, VistaJet has flown corporations, governments and private clients to 187 countries worldwide. Founded in 2004 by Thomas Flohr, the company pioneered an innovative business model where customers pay only for the hours they fly, free of the responsibilities and asset risks linked to aircraft ownership. VistaJet's signature Program service offers customers a bespoke subscription of flight hours on its fleet of mid and long range jets, to fly them anywhere and at any time.

More VistaJet information and news at vistajet.com.

Information

Jennifer Tyler
VistaJet International
T: +44 (0) 203 617 3077
M: +44 (0) 7834 335505
jennifer.tyler@vistajet.com

James Leviton
Finsbury
T: +44 207 251 3851
VistaJet@finsbury.com



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: VistaJet Ltd via Globenewswire

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

Resverlogix Provides Unrestricted Educational Grant for Epigenetic Symposium at International Renal Congress25.5.2018 07:45Pressemelding

CALGARY, Alberta, May 24, 2018 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) today announced that on Friday, May 25, 2018, at the European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) Congress in Copenhagen, Denmark, the Company is supporting a symposium titled: "Epigenetics in CKD & CVD: A potential breakthrough therapy?" The symposium highlights the role of epigenetics and BET-inhibition in chronic kidney disease and cardiovascular disease, especially in patients with diabetes mellitus, and the significant unmet need that still exists in this patient population. The symposium is co-chaired by Vincent M. Brandenburg, MD - Nephrologist, Aachen, Germany and Kamyar Kalantar-Zadeh, MD - UC Irvine School of Medicine, Irvine, CA, USA, both leading scientists also serving as advisors to Resverlogix's Renal program. The speakers and agenda are as follows: Introduction Vincent M. Brandenburg, MD - University Hospital of the RWTH

Atico Reports Consolidated Financial Results for the First Quarter of 201824.5.2018 22:30Pressemelding

(All amounts expressed in US dollars, unless otherwise stated) VANCOUVER, British Columbia, May 24, 2018 (GLOBE NEWSWIRE) -- Atico Mining Corporation (the "Company" or "Atico") (TSX.V:ATY) (OTC:ATCMF) today announced its financial results for the three months ended March 31, 2018, posting a net income of $0.4 million. Fernando E. Ganoza, CEO and Director, commented, "The strong production and all-in sustaining cash cost of $1.85 achieved this quarter is not reflected in the financial results as a large concentrate shipment was delayed to the second quarter, along with the revenue associated with those tonnes. The shipping schedule is expected to stabilize during the second quarter, where we will then benefit from the additional shipped concentrate and recognized revenue. We anticipate strong financial results in the next quarter." Mr. Ganoza continued, "Our emphasis will continue to be on further strengthening our balance sheet, improving production costs and most importantly regional

Luxembourg Announced as SNOMED International's Newest Member24.5.2018 15:16Pressemelding

London, United Kingdom, May 24, 2018 (GLOBE NEWSWIRE) -- SNOMED International and Agence eSanté Luxembourg are pleased to announce that Luxembourg has joined the organization as its thirty-second Member. Luxembourg, one of the leading nations in the area of information and communication technology, has set the development of eHealth technologies as a high priority. Agence eSanté, Luxembourg's national agency for the exchange and sharing of medical data, has set an overall mission to facilitate clinical information exchange both within Luxembourg and across other international actors. To work towards this reality, the agency has taken part in discussions about standardization across Europe, a contributing building block achieved with its membership in SNOMED International. With their membership, Agence eSanté has committed their support for the use of structured clinical terminology. When applied to the health sector, interoperability ensures that information systems, and through them h

SEMAFO Signs Underground Mining Services Contract with AUMS24.5.2018 14:00Pressemelding

MONTREAL, May 24, 2018 (GLOBE NEWSWIRE) -- SEMAFO Inc. (TSX:SMF) (OMX:SMF) reports that it has signed a mining services contract with African Underground Mining Services ("AUMS") to provide turnkey mining services for Siou underground. AUMS is a well-known and reputable mining contractor with underground experience in Burkina Faso and across Africa. Under the mining services contract, AUMS will be responsible for supplying the mining fleet and a skilled labour force for Siou underground in addition to ensuring development, production and auxiliary services. SEMAFO will provide technical services including geology and engineering as well as leveraging the existing surface infrastructure at Mana. The mining services contract has a term of 70 months. The economic terms of the mining services contract are consistent with the economics presented in the Mana pre-feasibility study filed March 29, 2018 on SEDAR. Preparatory work has already commenced on Siou underground with full project deplo

Merus Announces First Patient Dosed in Phase 1 Clinical Trial of MCLA-158 in Patients with Solid Tumors24.5.2018 13:00Pressemelding

- IND Accepted in April by the U.S. FDA for MCLA-158 - UTRECHT, The Netherlands, May 24, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that the first patient has been dosed in a Phase 1, first-in human clinical trial of MCLA-158 in patients with solid tumors with an initial focus on metastatic colorectal cancer. The trial will be conducted in Europe, where several Clinical Trial Applications (CTAs) have been approved to date. The Company also announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for MCLA-158, which was accepted by the FDA in April 2018. With this acceptance, Merus plans to open additional sites for this trial in the United States. MCLA-158 is designed to bind to cancer stem cells expressing leucine-rich repeat-containing G protein-coupled receptor 5 (Lgr5) and epidermal grow

PRA Named International Clinical Research Company of the Year24.5.2018 10:00Pressemelding

RALEIGH, N.C., May 24, 2018 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ:PRAH) is pleased to announce it was recognized by PharmaTimes as the International Clinical Research Company of the Year. This is the fifth year in a row that PRA has received this award. "This award celebrates excellence in the clinical research industry and we are honored to once again be recognized by our peers," said Colin Shannon, President and Chief Executive Officer. "This award is possible thanks to the incredibly talented PRA team members we have working around the world who are deeply committed to their work in bringing new and life-saving therapies to the patients who need them." PRA also swept the Clinical Research Associate and Clinical Trial Administrator categories capturing a total of 11 awards. These awards follow PRA's recognition earlier this month in the PharmaTimes Americas competition where PRA also received 11 awards, including Company of the Year. The PharmaTimes, International Cli

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom